JPS60130394A - Novel antibiotic sf-2324 substance, preparation, and use thereof - Google Patents

Novel antibiotic sf-2324 substance, preparation, and use thereof

Info

Publication number
JPS60130394A
JPS60130394A JP58237917A JP23791783A JPS60130394A JP S60130394 A JPS60130394 A JP S60130394A JP 58237917 A JP58237917 A JP 58237917A JP 23791783 A JP23791783 A JP 23791783A JP S60130394 A JPS60130394 A JP S60130394A
Authority
JP
Japan
Prior art keywords
substance
potassium salt
culture
antibiotic
magnetic resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP58237917A
Other languages
Japanese (ja)
Inventor
Yukio Takase
幸男 高瀬
Mamoru Ishihara
守 石原
Tadashi Nakazawa
中沢 正
Toru Sasaki
徹 佐々木
Takashi Shomura
庄村 喬
Masaji Sezaki
瀬崎 正次
Tetsuo Ishikawa
哲夫 石川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Priority to JP58237917A priority Critical patent/JPS60130394A/en
Publication of JPS60130394A publication Critical patent/JPS60130394A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

PURPOSE:To obtain a novel antibiotic SF-2324 showing strong coccidium action, by cultivating a specific strain belonging to the genus Actinomadura. CONSTITUTION:Actinomadura.sp. SF-2324(FERM-P 7346) is cultivated under aerobic conditions especially by submerged culture. Preparation of SF-2324 substance reaches the maximum accumulation usually in 3-10 days by shaking culture or tank culture. The minimum growth inhibition concentration of SF-2324 substance to various microorganism measured by agar dilution method is shown as follows. Staphylococcus aureus FDA209JC-1; 1.56, Staphylococcus epidermidis ATCC14990; 1.56, Bacillus anthracis No.119; 0.78, Salmonella typhi O-901-W; >100, Pseudomonas aeruginosa MB-3829; >100, etc.

Description

【発明の詳細な説明】 本発明は新規抗生物質SF’−2324物質、その製造
法及び用途に関する・ 本匝明者らは、アクチノマデユラ属に属する特定の菌株
を培養すると、各種細菌に対して強い発育阻止作用を有
する物質が培養物中に生産、蓄積されることを見い出し
、その有効物質を採取することに成功した。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel antibiotic SF'-2324 substance, its production method and uses. We discovered that a substance with a growth-inhibiting effect was produced and accumulated in culture, and succeeded in collecting the effective substance.

さらに本発明者らは、この有効物質を単離、精製し、そ
の性質を検討した結果・既知の物rとは異なる新規抗生
物質であることを見出し、この有効物質を8F−232
4物質と命名した。
Furthermore, the present inventors isolated and purified this effective substance, and as a result of examining its properties, discovered that it is a new antibiotic different from known substances.
Four substances were named.

したがって第一の本発明は新規抗生物質S F −23
24物質及びその塩を要旨とするものでおる・本発明の
5F−2324物質は下記の理化学的性状を有する@ fll 色及び性状:無色針状結晶。
Therefore, the first invention is a novel antibiotic SF-23.
The 5F-2324 substance of the present invention has the following physical and chemical properties.Color and properties: Colorless acicular crystals.

(2)元素分析値: 遊離酸C60,,17%、H8,87チ。(2) Elemental analysis value: Free acid C60, 17%, H8,87.

NQ % ナトリウム塩 C59,80%、H8,76%、NO%
(3) 分 子量、カリウム塩 105581M8す[
リウム塩 103981M8 (4)融 点:遊離酸 128〜+ 30 ’Cカリウ
ム塩 155〜l 57 ’C (5) 比旋光度: 〔α]25+15.7°(c=l
、メl/−/L、)1G) 紫外線吸収スはクトル °
 210mμ 以上で特徴的な吸収は示さない。
NQ% Sodium salt C59,80%, H8,76%, NO%
(3) Molecular weight, potassium salt 105581M8 [
Lium salt 103981M8 (4) Melting point: Free acid 128~+30'C Potassium salt 155~l 57'C (5) Specific rotation: [α]25+15.7° (c=l
, Mel/-/L, )1G) Ultraviolet absorption is
No characteristic absorption is shown above 210 mμ.

(7) 赤外線吸収スペクトル :遊離酸のKBr錠に
よる吸収スペクトルを第1図に示す。カリウム塩のKB
r錠による吸収スはクトルを第2図に示すO +81 核磁気共鳴スペクトル:カリウム塩の水素核磁
気共鳴スペクトルを第3図に示す。カリウム塩の炭素核
磁気共鳴スはクトルを第4図に示す0 (9) シリカゲル薄層りaマドグラムのRf 値:R
f=0.28 (酢酸エチル) Rf=0.23 (酢酸エチル:クロロホルム−=S 
: + )R,=o、ag (酢酸エチルニア七トン=
5:I)〔1呈色反応:硫酸及びレミュー試薬K11a
性・ニンヒドリン試薬に陰性〇 αυ i M 性:へキサン、クロロホルム、酢酸エチ
ル、アセトン及びメタノールに易溶0水に難溶〇 5F−2324物質の寒天希釈法で測定した各種微生物
知対する最小発育阻止濃塵を第1表Vこ示す0また、本
物質は強い抗コクシジウム作用を有することもiめられ
た。81’i’−2324物質の毒性はLD5゜(マウ
ス、皮下注射)値が6.2η/kyである0/ 前記したS [” −2324物質の理化学的性状およ
び生物学的性状を既知抗生物質のそれと比較すると、所
謂、ポリエーテル系イオノフオア抗生物質に分類される
と考えられる。しかしながら、ポリエーテル系イオノフ
オア抗生物質の中で一分子量が1000曲後の物質はに
一41A(f+子敞962)、に−41B(分子量+o
6o)及びA−130B(分子量994)が知られてい
るが、5F−2324物質とは分子量その他の理化学的
性状が異なる・したがって、5F−2324物質は新規
抗生物質である。
(7) Infrared absorption spectrum: The absorption spectrum of the free acid in KBr tablets is shown in FIG. KB of potassium salt
The absorption spectrum by the r tablet is shown in Figure 2. O +81 Nuclear magnetic resonance spectrum: The hydrogen nuclear magnetic resonance spectrum of the potassium salt is shown in Figure 3. The carbon nuclear magnetic resonance spectrum of potassium salt is shown in Figure 4.0 (9) Rf value of silica gel thin layer a madogram: R
f=0.28 (ethyl acetate) Rf=0.23 (ethyl acetate:chloroform-=S
: + ) R, = o, ag (7 tons of ethylnia acetate =
5:I) [1 Color reaction: sulfuric acid and Lemieux reagent K11a
Characteristics: Negative to ninhydrin reagent〇αυ i M Characteristic: Easily soluble in hexane, chloroform, ethyl acetate, acetone and methanol 0 Slightly soluble in water 〇Minimal growth inhibition against various microorganisms measured by agar dilution method of 5F-2324 substance It was also found that this substance had a strong anti-coccidiosis effect. The toxicity of substance 81'i'-2324 is LD5° (mouse, subcutaneous injection) value of 6.2η/ky. Compared to that of 1, it is considered to be classified as a so-called polyether ionophore antibiotic. However, among the polyether ionophore antibiotics, the substance with a molecular weight of 1000 is Ni-41A (f+zi 962). , Ni-41B (molecular weight + o
5F-2324 substance is a new antibiotic.

本発明の新規抗生物質5F−2324物質はアクチノマ
デユラ属に属する抗生物質5F−2324物質生産菌を
培養し、その培養物から5F−2324物質を採取する
ことによって製造される。か\る5F−2324物質の
製造法は第二の本発明を構成する・本発明の新規抗生物
質5F−2324物質の生産菌の一例としては、本発明
者らにより静岡県清水市の土壌より新たに分離された5
F−2324株がある。
The novel antibiotic 5F-2324 substance of the present invention is produced by culturing an antibiotic 5F-2324 substance-producing bacterium belonging to the genus Actinomadeula and collecting the 5F-2324 substance from the culture. The method for producing the 5F-2324 substance constitutes the second invention. As an example of the producing bacteria of the novel antibiotic 5F-2324 substance of the present invention, newly separated 5
There is F-2324 strain.

水沫の菌学的性状は下記の通りである。The mycological properties of the water droplets are as follows.

■、形態学的性質 基中菌糸はよく伸長分枝し、その直径は約0・5μmで
ある0寒天培地及び液体培地のいずれにおいても基中菌
糸の分断は通常みられない。一般に気菌糸の着生は貧弱
であるが、スターチ寒天で白色の気菌糸を着生し、胞子
層成も認められる。なお、気菌糸及び胞子の形成は28
°Cよりも37°Cの方が良好である。気菌糸の分枝は
単純分枝で車軸分枝はみられない。電子顕微鏡で観察す
ると、気菌糸上に胞子連鎚がみられ、その形状はループ
状〜短いらせん状である。胞子の連鎖は3〜IQ個の場
合が多い@胞子は楕円形〜卵形で、0.6〜1、OXO
,8〜1,2μmの大きさを有し、その表面はスムース
(ややしわ状)である〇 2、各種培地上の生育状態 8F−2324株の各種培地上の生育状態を第2表に示
す@観察は14〜21日培譬後に実施した。
(2) Morphological properties The basal hyphae are well elongated and branched, and their diameter is approximately 0.5 μm.No division of the basal hyphae is usually observed in either agar medium or liquid medium. Generally, the attachment of aerial mycelium is poor, but white aerial mycelium is attached on starch agar, and spore layer formation is also observed. In addition, the formation of aerial mycelia and spores is 28
37°C is better than 37°C. The branches of the aerial hyphae are simple branches, and no axle branches are observed. When observed with an electron microscope, spore chains are seen on the aerial mycelium, and the shape is loop-like to short spiral. Chains of spores often have 3 to IQ pieces @Spores are oval to oval, 0.6 to 1, OXO
, 8 to 1.2 μm in size, and its surface is smooth (slightly wrinkled) 〇2. Growth status on various media Table 2 shows the growth status of strain 8F-2324 on various media. @Observation was carried out after 14-21 days of culture.

培養温度は28°Cであるが、一部の培地Vこついては
37°Cにおける状態についても記載した。
Although the culture temperature was 28°C, conditions at 37°C were also described for some of the culture media.

8、生理的性質 +11 生育温度範囲:イースト麦芽寒天における15
〜45°Cの温度範囲で生育し、28〜40°Cが最適
温度である。
8. Physiological properties +11 Growth temperature range: 15 in yeast malt agar
It grows in a temperature range of ~45°C, with an optimum temperature of 28-40°C.

(2) ゼラチンの液化 :陽性(20°C121日間
培養) (3) スターチの加水分解:陰性(28°C137°
C914日間培養) (4) 硝酸塩の還元 :陽性(28°C137°C1
14日間培養) (5) 脱脂乳をはプトン化及び凝固する( 280C
、37”C。
(2) Liquefaction of gelatin: Positive (cultured at 20°C for 121 days) (3) Hydrolysis of starch: Negative (28°C, 137°
C914 day culture) (4) Nitrate reduction: Positive (28°C137°C1
14 days of culture) (5) Skim milk is transformed and coagulated (280C
, 37”C.

14日間培養)・ (6) 耐塩性:5%の食塩存在下で生育するが、7チ
では生育しない。
14-day culture)・(6) Salt tolerance: Grows in the presence of 5% salt, but does not grow in the presence of 7% salt.

(7)メラニン様色素の生成 : トリジトン・イース
トエキストラクト・ブロス、ペプトン・イーストエキス
トラクト・鉄寒天及びチロシン寒天で陰性。
(7) Formation of melanin-like pigments: Negative with triditone yeast extract broth, peptone yeast extract, iron agar, and tyrosine agar.

4・ 炭素源の利用性(プリドハム・ゴツトリーズ際天
培地使用)−ル (2) 利用が疑わしい糖: D−7ラク ドース、 
i −イノシトール、ラフィノース (3) 利用しない糖 :L−アラビノース、D−キシ
ロース、L−ラムノース、シュクロース5、細胞壁組成 8F−2324株の全細胞加水分解物中にメソ−ジアミ
ノピメリン酸が認められた0 以上の性状より、8F−2324株は放線菌の中で、ア
クチノマデユラ(Acttnomadura ) 属に
最も近似している。したがって、本発明者らはS F 
−2324株をアクチノマデユラ・エスピー・5F−2
324(AcLtnoma、dura sp、5F−2
324)と称することとしたO なお、本菌株は工業技術院微生物工業技術研究所に昭和
58年11月18日以来寄託されており、その寄託番号
は機工研菌寄第7346号(F’l1M P−7346
)である。
4. Utilization of carbon source (use of Prydham-Gottries celestial medium) - Rule (2) Sugars whose use is questionable: D-7 Lacdose,
i-inositol, raffinose (3) Unused sugars: L-arabinose, D-xylose, L-rhamnose, sucrose 5, cell wall composition 8 Meso-diaminopimelic acid was observed in the whole cell hydrolyzate of strain F-2324 Based on the above characteristics, strain 8F-2324 is most similar to the genus Acttnomadura among actinomycetes. Therefore, we S F
-2324 strain Actinomadeura sp. 5F-2
324 (AcLtnoma, dura sp, 5F-2
This strain has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology since November 18, 1981, and its deposit number is Kikoken Bacteria Deposit No. 7346 (F'l1M). P-7346
).

8F−2324株は他の放線菌の多くの菌株の場合とえ
は、紫外線、エックス線、放射線、薬品等を用いる人工
的変異手段で変異[2得るものであり、いずれの変異株
であっても8F−2324物質の生産能を有するアクナ
ノ1デユラ属の菌株はすべて本発明の方法に使用するこ
とができる。
The 8F-2324 strain is one that can be mutated [2] by artificial mutagenesis methods using ultraviolet rays, X-rays, radiation, chemicals, etc. in many other strains of actinomycetes, and any mutant strain is Any strain of the genus Acunano 1 dura that has the ability to produce the 8F-2324 substance can be used in the method of the present invention.

本発明の方法では、帥記菌昧を通常の微生物が利用しう
る栄養物を含有する培地で培養する0栄養源としては、
従来放射菌の培養に利用されている公知のものが使用で
きる。たとえば、炭素源としてグルコース、水あめ、グ
リセロール、糖みっ・植物油、動物油等が使用できる。
In the method of the present invention, the nutrient source for culturing the P. spp. in a medium containing nutrients that can be used by ordinary microorganisms is:
Known materials conventionally used for culturing Actinobacteria can be used. For example, glucose, starch syrup, glycerol, sugar syrup/vegetable oil, animal oil, etc. can be used as the carbon source.

また窒素源として大豆粉、小麦胚芽、肉エキス、はプト
ン、酵母エキス、コーンステイープリカー、綿実がす・
魚粉、硫酸アンモニウム、硝酸ソーダ、尿素等を使用し
得る。その他必安に応じて炭酸カルシウム。
Nitrogen sources include soybean flour, wheat germ, meat extract, cornstarch, yeast extract, cornstap liquor, cottonseed gas, etc.
Fishmeal, ammonium sulfate, sodium nitrate, urea, etc. may be used. Other calcium carbonate as required.

塩化ナトリウム、硫酸マグネシウム、塩化コバルト、燐
酸塩等の無機塩類を添加するほか、菌の発育を助け、5
F−2324物質の生産を助長し、促進する有機及び無
機物を適当に添加することができるO 培養法としては、好気的条件下での培養法、特に深部培
養法が最も適している。培養に適当な温度は15〜45
°Cであるが、多くの場合28〜37Ocの範囲が望ま
しい。
In addition to adding inorganic salts such as sodium chloride, magnesium sulfate, cobalt chloride, and phosphates, it helps the growth of bacteria and
As the O 2 culture method, in which organic and inorganic substances that promote and promote the production of the F-2324 substance can be appropriately added, a culture method under aerobic conditions, particularly a deep culture method, is most suitable. The appropriate temperature for culturing is 15-45
°C, but in most cases a range of 28 to 37 °C is desirable.

SF’−2324物質の生産は培地や培養条件に−より
異なるが、振盪培養、タンク培養ともに通常3〜1゜日
間でその蓄積が最高に達する・ かく生産される5F−2324物′jMは前記する理化
学的性状を有するので、その性状に従って培養液から抽
出、精製することが可能であるが、特に以下の方法によ
り効率的に抽出、精製できる〇すなわち、有効成分を含
む培養物に酢酸エチル等の水と混和しない有機溶媒を加
えて攪拌抽出する。あるいは培養物から固形物を炉別し
たP液に酢酸エチル等の水と混合しない溶葬を加えて攪
拌抽出する。一方、固形物はアセトン等の水と自由に温
合する溶媒を加えて攪拌し、固形分から有効成分を抽出
し、有機溶媒を留去した後、酢酸エチル等の有機溶媒で
有効成分を抽出する。
The production of SF'-2324 substance differs depending on the culture medium and culture conditions, but in both shaking culture and tank culture, the accumulation usually reaches its maximum within 3 to 1° days.The 5F-2324 substance produced in this way is Since it has physical and chemical properties, it is possible to extract and purify it from the culture solution according to its properties, but it can be particularly efficiently extracted and purified by the following method. In other words, it can be extracted and purified efficiently by the following method. Add an organic solvent that is immiscible with water and extract with stirring. Alternatively, a solution that does not mix with water, such as ethyl acetate, is added to the P solution obtained by separating the solid matter from the culture, and the mixture is stirred and extracted. On the other hand, the solid substance is stirred with a solvent such as acetone that warms freely with water, the active ingredient is extracted from the solid substance, the organic solvent is distilled off, and the active ingredient is extracted with an organic solvent such as ethyl acetate. .

抽出液の溶媒を留去して得た油状物質をn−ヘキサン等
の溶媒を加えて抽出し、残渣を炉別するO抽出液の溶媒
を留去して得た油状物質を少量の溶媒に溶解し、シリカ
ゲル、アルミナ、ゲル濾過剤等の担体を適宜組み合わせ
て使用し、5F−2324物質を単離する6 単離された8F−2324物質を酢酸エチル等の有機溶
媒に溶解し、酸性水と攪拌する。有機溶媒を純水で洗浄
後、有機溶媒を減圧濃縮し、得られた残留物をメタノー
ル−水、エタノール−水、アセトン−水等の溶媒系を用
いて結晶化することにより8F−2324物質の結晶を
得る。なお、S F −2324物質は種々の塩、たと
えば、ナトリウム塩、カリウム塩、アンモニウム塩とし
て得ることができるO8t’−2324物質の検定に当
っては、バチルス・ステア ry f −% フィラス
(Bacillus stearoLhe−rmoph
ilus )を検定菌とする生物学的検定法を用いる。
The oily substance obtained by distilling off the solvent of the extract is extracted by adding a solvent such as n-hexane, and the residue is filtered. 6. Dissolve the isolated 8F-2324 substance in an organic solvent such as ethyl acetate, and isolate the 5F-2324 substance using an appropriate combination of carriers such as silica gel, alumina, and gel filtration agents. and stir. After washing the organic solvent with pure water, the organic solvent is concentrated under reduced pressure, and the resulting residue is crystallized using a solvent system such as methanol-water, ethanol-water, acetone-water, etc. to obtain 8F-2324 substance. Obtain crystals. In addition, SF-2324 substance can be obtained as various salts, for example, sodium salt, potassium salt, and ammonium salt. In assaying O8t'-2324 substance, Bacillus stearoLhe -rmoph
A biological assay method using S. illus ) as the test bacteria is used.

この検定法では5F−2324物質が62.5μ?/ 
ml−500μf/−の濃度範囲において、その対数と
阻止円径との間に直機的関係を示し、それぞれI 7,
9 mm−20,8vmの阻止用(faint zon
e )を与える。
In this assay method, 5F-2324 substance is 62.5μ? /
In the concentration range of ml-500 μf/-, there is a direct relationship between the logarithm and the inhibition circle diameter, and I 7,
9 mm-20,8vm blocking (faint zone
e).

さらに本発明は抗生物質5r−2324物質を有効成分
とする抗コクシジウム剤を第三の発明として提供するも
のである。
Furthermore, the present invention provides, as a third invention, an anti-coccidiosis agent containing the antibiotic 5r-2324 substance as an active ingredient.

本発明の8F−2324物質を抗コクシジウム剤として
使用する場合は、そのまま直接経口投与するか、あるい
は飼料に添加して投与するのがよい0飼料となりうるも
のとしては、たとえば配合飼料または大麦粉、小麦粉、
裸麦粉、とうもろこし粉。
When the 8F-2324 substance of the present invention is used as an anticoccidial agent, it can be administered orally directly as it is, or it can be administered by adding it to feed. Examples of possible feeds include compound feed, barley flour, flour,
Bare flour, corn flour.

大豆粉、大豆粕、菜種粕、米ぬか、脱脂ぬか、馬れいし
よ粉、かんしょ粉、その他の澱粉類、とうふ粕、酵母、
魚粉、醗酵残留物等を挙けることができる6また、通常
用いられている飼料添加物、たとえば各種ビタミン類、
ミネラル類、防腐剤。
Soybean flour, soybean meal, rapeseed meal, rice bran, defatted rice bran, horse flour, Kansho powder, other starches, tofu meal, yeast,
Examples include fishmeal, fermentation residues, etc.6 Also, commonly used feed additives, such as various vitamins,
Minerals, preservatives.

酵素製剤、たん白質、炭水化物、アミノ酸類、解熱剤、
鎮静剤、消炎剤、殺菌剤などに配合して用いてもよい。
Enzyme preparations, proteins, carbohydrates, amino acids, antipyretics,
It may be used in combination with sedatives, anti-inflammatory agents, bactericidal agents, etc.

つぎに本発明に従う5F−2324物質の製造法の実維
例を示すが、ここに例示しない多くの変形または修飾手
段音用い得ることは勿論である・実施例1 種菌としてアクチノマデユラ・エスピー8F−2324
株(機工研菌寄第7346号)を用いた。種培地として
スターチ1.0%、グルコース1.01ヘフトン0.5
%、肉エキス0.2%、酵母エキスI)、3憾、大豆粉
0.21炭酸カルシウム0.2チを含む培地を用いた・
また、生産培地としてグルコース2.5%、コーン・ス
テイープ・リカー1.5 %。
Next, an actual example of the method for producing the 5F-2324 substance according to the present invention will be shown, but it goes without saying that many modifications or modification methods not exemplified here may be used.Example 1 Actinomadeura sp.
strain (Kikoken Bacteria No. 7346) was used. Starch 1.0%, glucose 1.01, hefton 0.5 as seed medium
%, meat extract 0.2%, yeast extract I), soybean flour 0.21%, calcium carbonate 0.2%.
Also, the production medium was 2.5% glucose and 1.5% corn steep liquor.

サングレイン(サントリー社製)1.0%、ファーマメ
ディア(トレイダース・オイルミル社1iり0.51塩
化コバルl−0・001襲・硫酸亜鉛0・0005チの
組成からなる培地をpH7,0に調整後、さらに 、炭
酸カルシウム0.3%を添加した培地を用いたOイース
ト麦芽斜面寒天培地に生育した1本分の種菌をかきとっ
て曲記の種培地20−を含む100−容三角フラスコ1
本に接種し、280C16日間振盪培養した。さらにこ
れを種培地80mを含む500−容の三角フラスコ2本
に10%の割合で接種し。
A medium consisting of 1.0% Sungrain (manufactured by Suntory), Pharmamedia (Traders Oil Mill Co., Ltd.), 0.51% cobal chloride, 0.001% zinc sulfate, and 0.0005% zinc sulfate was adjusted to pH 7.0. After the adjustment, one inoculum grown on the O yeast malt slant agar medium using a medium supplemented with 0.3% calcium carbonate was scraped off and placed in a 100-capacity Erlenmeyer flask containing the seed medium 20-20. 1
The cells were inoculated into 280C cells and cultured with shaking for 16 days. Furthermore, this was inoculated at a rate of 10% into two 500-volume Erlenmeyer flasks containing 80 m of seed medium.

28°C13日間振盪培養し、これを種培養とした0鋪
記の生産培地80m1を含む500−容三角フラスコ3
5本に上記の種培養を6%ずつ接種し、288C,6日
間振盪培養した0 培養終r後、33本分の培養物を合わせたものを濾過助
剤を用いて濾過したO得られた菌体を70チアセトン水
で抽出し、菌体抽出液3.5tを得た。さらに菌体抽出
液を減圧濃縮してアセトンを留去した水層1.5Lに、
酢酸エチル1.56を加えて振盪し、有効成分を酢酸エ
チル層へ抽出した。
A 500-capacity Erlenmeyer flask 3 containing 80 ml of a production medium of 0.5 mm was cultured with shaking at 28°C for 13 days and used as a seed culture.
Five bottles were inoculated with 6% each of the above seed cultures and cultured with shaking at 288C for 6 days. The bacterial cells were extracted with 70% thiacetone water to obtain 3.5 tons of bacterial cell extract. Furthermore, the bacterial cell extract was concentrated under reduced pressure to remove acetone, and the aqueous layer was added to 1.5 L.
1.56 ml of ethyl acetate was added and shaken, and the active ingredients were extracted into the ethyl acetate layer.

この酢酸エチル層を減圧濃縮し、黒褐色の油状物質94
2・7岬を得たO油状物質942.7〜に50−のへキ
サンを加え、30分間攪拌抽出し、残渣を炉別した。こ
の操作を2回くり返して得られたへキサン層を減圧濃縮
し、650■の油状物質を得たOこの油状物質650■
を5 mlのクロロホルムに溶解し、シリカゲル(フコ
−ゲルC−20O,和光純薬社製)の65TntO塔に
かけ、クロロホルム−酢酸エチル(IQ:l)の混液3
00m1で洗浄した0さらにクロロホルム−酢酸エチル
(4:I)の混液260−で洗浄した後、クロロホルム
−酢酸エチル(1:10)の混液500 mlで展開し
たところ・活性物質が溶出された・この活性画分の中で
、アセトン−酢酸エチル(+:S)の混液を展開溶媒と
するシリカゲル薄層(キーゼルゲル5714 、メルク
社製)クロ1トゲラフイーで単一スポットを与える両分
を合わせ減圧濃縮したところt’ +14.7ηのS卜
2324′吻質を白色粉末として得た。
This ethyl acetate layer was concentrated under reduced pressure, and a blackish brown oily substance 94 was obtained.
50-hexane was added to 942.7 ~ of the O oily substance obtained from Cape 2.7, extracted with stirring for 30 minutes, and the residue was filtered. This operation was repeated twice and the obtained hexane layer was concentrated under reduced pressure to obtain 650 cm of an oily substance.
was dissolved in 5 ml of chloroform, applied to a 65TntO column of silica gel (Fuko-gel C-20O, manufactured by Wako Pure Chemical Industries, Ltd.), and added to a mixed solution of chloroform-ethyl acetate (IQ: l).
After washing with 260ml of a mixture of chloroform and ethyl acetate (4:I), it was developed with 500ml of a mixture of chloroform and ethyl acetate (1:10).The active substance was eluted. Among the active fractions, a thin layer of silica gel (Kieselgel 5714, manufactured by Merck & Co., Ltd.) using a mixture of acetone and ethyl acetate (+:S) as a developing solvent gave a single spot using a chromatography method, and both fractions were combined and concentrated under reduced pressure. As a result, S-2324' rostrum with t' +14.7η was obtained as a white powder.

残りの活性画分を濃縮乾固して得た361・9■の粗粉
末を少数のメタノールに溶解し、メタノールで充填シた
100dのセファデックスL +−1−20の塔にかけ
、メタノールで展開して、活性画分を濃縮乾固し、33
9.31ngの粗粉末を得た。この粗粉末339.3 
qを少鯰のりaoホルムに溶解し、クロロホルムで充填
したシリカゲル(ワコーゲルC−200、和光紬薬社製
)の塔にかけ、りooホルム−アセトン(+0:+)の
混液670dで塔を洗浄した後、クロロホルム−アセト
ン(5:l)の混液で溶出した。溶出された活性画分の
中で、前述したシリカゲル薄層クロマト−グラフィーで
単一スゼ・ソトか共ゆ入部;l;J?、を遍流故1韻1
−てI’lA、2噌の5F−2324物質を白色θ末と
して得た@実施例2 実施列1と同様の方法で培養、絹製して得られた粗粉末
446mgを少・駄の酢酸エチルに溶解し。
The remaining active fraction was concentrated to dryness to obtain a crude powder of 361.9 cm, which was dissolved in a small amount of methanol, applied to a 100 d Sephadex L +-1-20 column filled with methanol, and developed with methanol. The active fraction was concentrated to dryness, and 33
9.31 ng of coarse powder was obtained. This coarse powder 339.3
q was dissolved in chloroform-filled silica gel (Wakogel C-200, manufactured by Wako Tsumugi Pharmaceutical Co., Ltd.), and the tower was washed with 670 d of a mixed solution of chloroform-acetone (+0:+). Afterwards, the mixture was eluted with a mixture of chloroform-acetone (5:l). Among the eluted active fractions, the silica gel thin layer chromatography described above revealed a single Sze-Soto-J? , 1 rhyme 1
- I'lA, 2 scoops of 5F-2324 substance were obtained as white θ powder@Example 2 446 mg of the crude powder obtained by culturing and making silk in the same manner as in Example 1 was mixed with a small amount of acetic acid. Dissolve in ethyl.

分堰用シリカゲル薄層(キーゼルゲル5744.20X
2Qcm、メルク社a)5改に直線状にチャージし、酢
酸エチルとクロロホルムを5対10割合で混合し/ζ展
開溶好で展開した。
Thin layer of silica gel for branch weirs (Kieselgel 5744.20X
2Qcm, Merck & Co., Inc. a) 5 modified was charged linearly, and ethyl acetate and chloroform were mixed at a ratio of 5:10/ζ development solution.

展開路r後、シリカゲル4層の両側を1crn幅に切断
し、10%硫酸水を散布の後、加熱し−Cスポットを検
出した。検出されたスポットに合わせてシリカゲルをか
き取り、かき取つ7ヒシリカゲルを100 mlの酢酸
エチルを用いて抽出した・酢酸エチル層を濃縮乾固して
+90りの白色粉末を得た。この白色粉末+00Lηを
50rn1.の酢酸エチルに溶解し、50ゴのO,IN
頃敵で攪拌油出した。さらに酢酸エチル層を150ゴの
純水で洗浄後、濃縮乾固して79〃lの白色粉末を得た
・この白色粉末をアセトン水に溶解し、アセトンを減圧
丁で留去の後、冷所に一皮静置した0こうして得られた
結晶をい取して60.8屑7の5F−2324物質の遊
離酸を無色針状結晶として得た□つき゛に5F−232
4物質が家禽類のコクシジウム症に対して優れた活性を
示すことを試験fllによって説明するが勿論本発明は
これによって限定されるものではない。
After the development path r, both sides of the 4 layers of silica gel were cut into a width of 1 crn, and after spraying 10% sulfuric acid water, heating was performed to detect the -C spot. The silica gel was scraped off according to the detected spots, and the scraped silica gel was extracted using 100 ml of ethyl acetate.The ethyl acetate layer was concentrated to dryness to obtain a +90% white powder. Add this white powder +00Lη to 50rn1. of ethyl acetate and 50 g of O,IN
Around that time, the enemy poured out stirring oil. Furthermore, the ethyl acetate layer was washed with 150 g of pure water and concentrated to dryness to obtain 79 l of white powder. This white powder was dissolved in acetone water, the acetone was distilled off using a vacuum knife, and then cooled. 5F-232
The excellent activity of the four substances against coccidiosis in poultry will be explained by the test, but the present invention is of course not limited thereto.

試馳例 試験方法:8日令の雄性白色レグホー7種のヒナを1群
5羽用い、6群設けた。第1群〜第4群には5F−23
24物質の純品粉末をそれぞれ0.002係、 0.0
03%、0.004チ及び帆005φの割合で均一に添
加した飼料を給与(−だ。第5群及び第6群には薬剤無
添加の飼料を給与した・各&11旧を給与開始の翌日に
、第1群〜第5群にはアイメリアデネラ(Eimeri
a tenellera ) +7)成熟オーシストを
1羽当り5XIO’個を経口的に感染せしめた・感染8
日後に全群のヒナの体重を測定後剖検し、盲腸病変の強
さの判定を行った。判定は角田らの基単に従い、−〜+
+++に区分し、これを0〜4の政情に変換した・さら
に、盲腸便1f中のオーシスト数を測定し、第3表に従
い請 求めた。また1体重については各群毎に増加率をめ、非
感染対照群の体重増加率’r+ 00として各群の相対
増体率を算出した。以上の結果より、次式を用いて抗コ
クシジウム指数(ACI)を算出した◇ ACI=(相対増体率+生存率)−(病変値+オーシス
ト値)第3表 オーシスト値の区分 0〜0.1 0 0.1〜1.0 1 2.0〜5.0 10 6.0〜 + 0.0 20 ≧11.0 40 試験結果: 5F−2324物質のACIについて第4
表に示す。S←’−2324物質はヒナの飼料に0.0
03係以上均一に添加して投与したとき著明にコクパノ
ジウム症全抑制しかつ毒性的な影響も示さなかったO
Trial example Test method: Six groups of 8-day-old male white Leghoe chicks of 7 species were used, with 5 chicks per group. 5F-23 for 1st to 4th groups
0.002 and 0.0 of each pure powder of 24 substances
Feed with feed uniformly added at a ratio of 0.03%, 0.004chi, and 0.005φ (-).The 5th and 6th groups were fed feed without chemical additives.The day after the feeding of each &11 old was started. In addition, the first to fifth groups include Eimeri adenella.
a tenellera) +7) 5XIO' of mature oocysts were orally infected per bird.Infection 8
Days later, the weights of the chicks in all groups were measured and necropsied to determine the strength of the cecal lesions. Judgment is based on the basics of Tsunoda et al. -~+
+++ and converted it into a political situation of 0 to 4.Furthermore, the number of oocysts in 1f of cecal stool was measured and billed according to Table 3. In addition, the relative weight gain rate of each group was calculated as the weight gain rate 'r+00 of the non-infected control group by calculating the weight gain rate for each group. Based on the above results, the anticoccidial index (ACI) was calculated using the following formula ◇ ACI = (relative gain rate + survival rate) - (lesion value + oocyst value) Table 3 Oocyst value classification 0 to 0. 1 0 0.1~1.0 1 2.0~5.0 10 6.0~ + 0.0 20 ≧11.0 40 Test results: 4th ACI of 5F-2324 substance
Shown in the table. S←'-2324 substance is 0.0 in chick feed
When 03 or more was added uniformly and administered, it significantly inhibited coccopanodiasis and showed no toxic effects.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図及び第2図はそれぞれSF’−2324物質の遊
離酸及びカリウム塩のKBr錠による赤外線吸収スペク
トルであり、第3図は8F−2324物質のカリウム塩
の水素核磁気共鳴スペクトルであり、第4図は5F−2
324物質のカリウム塩の炭素核磁気共鳴スペクトルで
ある。 手続補正書(自発) 昭和59年12月 28日 特許庁長官殿 1、事件の表示 昭和58 年特許願第 237917号2、発明の名称 新規抗生物質5F−2324物質、その製造法及び用途 3、補正をする者 事件との関係 特許出願火 柱 所 束ポ都中央区京橘二丁目4番16号物産ビル別
館 電話(591) 0261Lccwl rC# バ
十ITI 苗M5、補正の対象 明卸]曹の+6明の詳+1:nlな祝明のづ絢6袖正の
内容 tl) 明細礪 第12貞渠8行の1−放射菌」を「放
線菌」と子巾正する。 (2) 同、第14自下から第1行のI−(faint
 zone)Jを削除するっ (3)同、第20自第15行のrEimeria te
nelleraJをr gimeria tenell
a Jと補正する。
1 and 2 are infrared absorption spectra of the free acid and potassium salt of SF'-2324 substance by KBr tablet, respectively, and FIG. 3 is a hydrogen nuclear magnetic resonance spectrum of potassium salt of 8F-2324 substance, Figure 4 is 5F-2
324 is a carbon nuclear magnetic resonance spectrum of the potassium salt of substance 324. Procedural amendment (spontaneous) December 28, 1980 Mr. Commissioner of the Patent Office1, Indication of the case Patent Application No. 237917 of 19822, Title of the invention Novel antibiotic 5F-2324 substance, its manufacturing method and uses3, Relationship with the case of the person making the amendment Patent application fire pillar Address: Bussan Building Annex, 2-4-16, Kyotachibana, Chuo-ku, Chuo-ku Telephone: (591) 0261Lccwl rC# Baju ITI Nae M5, subject of amendment Ming Wholesale] Cao's +6 Details of Ming +1: Contents of Nl Shukumei Nozu Aya 6 Sode correction tl) Specification 1- Actinobacteria in line 8 of the 12th Teikyuu is corrected as ``actinobacteria.'' (2) Same, I-(faint
zone) Delete J (3) rEimeria te on the 15th line of the 20th
gimeria tenell
a Correct as J.

Claims (1)

【特許請求の範囲】 1・ 下記の特性を有する新規抗生物質8F’−232
4物質及びその塩: +t+ g及び性状:無色針状結晶 (2) 元累分析値: 遊離酸C60,17幅、 H8,131%。 80% ナトリウム塩 C5940%、H8,76%。 N0% (3) 分 子 量:カリウム塩 1055’sIMs
ナトリウム塩 1039 SIMS 141 融 点:遊tifG @ 12g 〜13o°
Cカリウム塩 155〜+57’c (5) 比 旋光 度−〔α)%7+−15;7°(c
=1.メタノール)(6) 紫外線吸収スはクトル :
 210−’μ 以上で特徴的な吸収は示さない0 (7) 赤外線吸収スペクトル :遊離酸のKBr錠に
よる吸収スペクトルを第1図に示す。カリウム塩のKB
r錠による吸収スペクトルを第2図に示す0 (8) 核磁気共鳴スペクトル :カリウム塩の水素核
磁気共鳴スはクトルを第3図に示す。カリウム塩の炭素
核磁気共鳴スはクトルを第4図に示す0 (91呈色反応:WI酸及びレミュー試薬に陽性、ニン
ヒドリン試薬に陰性。 01溶 解 性:へ牟サン、クロロホルム、酢酸エチル
、アセトン及びメタノールに易溶。 水に難溶。 2、アクナノ1デユラ槁に属する抗生物質5F−232
4物質生産菌を培養し、その培養物から8F−2324
物質を採取することを特徴とするS F −23’24
物質の製造法。 B、抗生物質5F−2324物質を有効成分とする抗コ
クシジウム剤。
[Claims] 1. Novel antibiotic 8F'-232 having the following properties:
4 substances and their salts: +t+ g and properties: colorless needle crystals (2) original cumulative analysis values: free acid C60, 17 width, H8, 131%. 80% Sodium salt C5940%, H8,76%. N0% (3) Molecular weight: Potassium salt 1055'sIMs
Sodium salt 1039 SIMS 141 Melting point: Free tifG @ 12g ~ 13o°
C potassium salt 155~+57'c (5) Specific optical rotation -[α)%7+-15;7°(c
=1. Methanol) (6) Ultraviolet absorption is a cutter:
No characteristic absorption is shown above 210-'μ. KB of potassium salt
The absorption spectrum of the r-tablet is shown in Figure 2.0 (8) Nuclear magnetic resonance spectrum: The hydrogen nuclear magnetic resonance spectrum of potassium salt is shown in Figure 3. The carbon nuclear magnetic resonance spectrum of potassium salt is shown in Figure 4. 0 (91 Color reaction: positive to WI acid and Lemieux reagent, negative to ninhydrin reagent. 01 Solubility: Hemusan, chloroform, ethyl acetate, Easily soluble in acetone and methanol. Slightly soluble in water. 2. Antibiotic 5F-232 belonging to Acunano 1 Deyura.
8F-2324 was obtained from the culture by culturing 4 substance-producing bacteria.
SF-23'24 characterized by collecting a substance
Method of manufacturing a substance. B. Anticoccidial agent containing antibiotic 5F-2324 substance as an active ingredient.
JP58237917A 1983-12-19 1983-12-19 Novel antibiotic sf-2324 substance, preparation, and use thereof Pending JPS60130394A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58237917A JPS60130394A (en) 1983-12-19 1983-12-19 Novel antibiotic sf-2324 substance, preparation, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58237917A JPS60130394A (en) 1983-12-19 1983-12-19 Novel antibiotic sf-2324 substance, preparation, and use thereof

Publications (1)

Publication Number Publication Date
JPS60130394A true JPS60130394A (en) 1985-07-11

Family

ID=17022354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58237917A Pending JPS60130394A (en) 1983-12-19 1983-12-19 Novel antibiotic sf-2324 substance, preparation, and use thereof

Country Status (1)

Country Link
JP (1) JPS60130394A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399675A (en) * 1989-06-01 1995-03-21 Pfizer Inc. Acidic polycyclic ether antibiotics and microorganisms useful in the production thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399675A (en) * 1989-06-01 1995-03-21 Pfizer Inc. Acidic polycyclic ether antibiotics and microorganisms useful in the production thereof

Similar Documents

Publication Publication Date Title
KR100333017B1 (en) Polycyclic anthelmintic agent, its preparation, its preparation, and compositions containing it
EP0132082B1 (en) Antibiotic/antitumor compounds and their production
GB2220657A (en) Antifungal fermentation product
PETERSEN et al. Production of cladospirone bisepoxide, a new fungal metabolite
EP0185456B1 (en) Cl-1577d and cl-1577e antibiotic/antitumor compounds, their production and use
EP0345735B1 (en) Glycoside antibiotics bu-3608d and bu-3608e
FR2568892A1 (en) NOVEL SANDRAMYCIN ANTIBIOTIC, PROCESS FOR PREPARING THE SAME, BIOLOGICALLY PURE CULTURE OF MICROORGANISM NOCARDIOIDES SP, ATCC NO 39419, AND PHARMACEUTICAL COMPOSITION CONTAINING SANDRAMYCIN
US20070142424A1 (en) Process for producing tacrolimus (FK-506) using vegetable oil as sole source of carbon
JPS63139191A (en) Antitumor antibacterial agent
US5164389A (en) Anthelmintic bioconversion products
JPH03173892A (en) Microbiologically transformed l-683 and 590 product
US4954641A (en) Novel antitumor antibiotic substance and a method for production thereof
CA2015940A1 (en) Antifungal agent
NZ227005A (en) Polycyclic compounds, derivatives of paraherquamide, from fermentation of penicillium charlesii mf 5123; pesticidal compositions
JPS60130394A (en) Novel antibiotic sf-2324 substance, preparation, and use thereof
EP0042172B1 (en) Antibiotic compounds, pharmaceutical compositions containing such compounds, process for production thereof
US4301248A (en) Fermentation process for making rachelmycin
CA2145204A1 (en) Antibiotic agents
JP2592468B2 (en) Benanomycins A and B, novel antibiotics and their production
FR2464265A1 (en) NOVEL DIHYDRO-3,4-HYDROXY-4 (HYDROXY-3-PYRIDYL-2) -5-METHYL-4H-PYRROLECARBOXAMIDE-2 ANTIBIOTIC SUBSTANCE, USEFUL AS A MEDICAMENT AND PROCESS FOR PREPARING THE SAME USING A NEW MICROORGANISM STRAIN
HU189578B (en) Process for preparing narasin
JPH05310766A (en) New antibiotic substance mi481-42f4-a and its produciton
GB2119787A (en) Pyrones
KR840000934B1 (en) Process for preparing antibiotic sf-2080 a and sf-2080 b
JP2002069075A (en) New physiologically active substance nk34896b and method for producing the same